Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Kremlin Spokesman Peskov Says He Has No Information On Incident In Poland

-Reuters

byBenzinga Newsdesk

November 15, 2022

1 minute read

-Reuters

Palantir Technologies Q3 EPS $0.04, Inline, Sales $392.00M Beat $385.02M Estimate

By Benzinga Newsdesk

Today, 3:19 AM

Palantir Technologies (NYSE:PLTR) reported quarterly earnings of $0.04 per share which met the analyst consensus estimate. This is a 104.26 percent increase over losses of $(0.94) per share from the same period last

PLTR

Pivotal Research Maintains Buy on Liberty Global, Lowers Price Target to $35

By Benzinga Newsdesk

Today, 3:19 AM

Pivotal Research analyst Jeffrey Wlodarczak maintains Liberty Global (NASDAQ:LBTYK) with a Buy and lowers the price target from $38 to $35.

LBTYK

Pfizer Inc Says Believe Benefits Of Chantix/Champix Outweigh The Very Low Potential Risks, If Any

By Bill Haddad

Today, 3:19 AM

-Reuters

PFE

News

AstraZeneca Announced PT027 PhIII Asthma Trials Met Primary Endpoints

By Charles Gross

Today, 3:19 AM

Positive high-level results from the MANDALA and DENALI Phase III trials of PT027 (albuterol/budesonide), at both 180/160mcg and 180/80mcg doses, met all primary endpoints demonstrating statistically significant benefits in patients with asthma versus individual components albuterol, also known as salbutamol (180mcg) and budesonide (160mcg).

AZN

Kremlin Spokesman Peskov Says He Has No Information On Incident In Poland

Related Posts

Palantir Technologies Q3 EPS $0.04, Inline, Sales $392.00M Beat $385.02M Estimate

Pivotal Research Maintains Buy on Liberty Global, Lowers Price Target to $35

Pfizer Inc Says Believe Benefits Of Chantix/Champix Outweigh The Very Low Potential Risks, If Any

AstraZeneca Announced PT027 PhIII Asthma Trials Met Primary Endpoints